AgomAb is a private biotherapeutics company developing regenerative therapies for structural tissue repair and functional organ recovery. Highly specific monoclonal antibodies are designed to treat a range of acute and chronic conditions that involve inflammatory, metabolic and fibrotic processes. By combining new scientific insights with robust development expertise, AgomAb is leading to the emergence of truly regenerative medicines.